who is selling?, page-35

Long time holder here. It's disappointing that the market hasn't been receptive to milestones achieved by the company, which raises the uncomfortable question of what exactly will it take? We are the furthest along in developing and marketing viable products than we have ever been. From a medical device perspective, the goods are there. With wise management of cash burn, we should do well. t makes no sense. The company could be doing a lot more to keep shareholders informed in a timely manner. Although Julian is great with replies, flippant 'we'll just keep doing what we're doing and the share price will take care of itself' responses do not sit well when clearly that is not reflected by the reality of a sub-performing share price. We need to see that our investment is worth it.